Business Description
Dr Reddy's Laboratories Ltd
NAICS : 325412
SIC : 2834
ISIN : US2561352038
Share Class Description:
RDY: ADRCompare
Compare
Traded in other countries / regions
DRREDDY.IndiaRDY.USARDDA.GermanyR1DY34.Brazil IPO Date
2001-04-11Description
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (22% of its generics sales), Russia (12%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.65 | |||||
| Equity-to-Asset | 0.72 | |||||
| Debt-to-Equity | 0.07 | |||||
| Debt-to-EBITDA | 0.23 | |||||
| Interest Coverage | 44.22 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 8.75 | |||||
| Beneish M-Score | -2.34 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 12 | |||||
| 3-Year EBITDA Growth Rate | 33.1 | |||||
| 3-Year EPS without NRI Growth Rate | 13.5 | |||||
| 3-Year FCF Growth Rate | 19 | |||||
| 3-Year Book Growth Rate | 14.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 4.14 | |||||
| Future 3-5Y Total Revenue Growth Rate | 7.34 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 73.7 | |||||
| 9-Day RSI | 66.23 | |||||
| 14-Day RSI | 60.88 | |||||
| 6-1 Month Momentum % | 13.61 | |||||
| 12-1 Month Momentum % | 19.57 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.55 | |||||
| Quick Ratio | 1.9 | |||||
| Cash Ratio | 0.77 | |||||
| Days Inventory | 172.72 | |||||
| Days Sales Outstanding | 100.3 | |||||
| Days Payable | 85.89 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.65 | |||||
| Dividend Payout Ratio | 0.13 | |||||
| 3-Year Dividend Growth Rate | 14.5 | |||||
| Forward Dividend Yield % | 0.65 | |||||
| 5-Year Yield-on-Cost % | 0.99 | |||||
| 3-Year Average Share Buyback Ratio | -0.1 | |||||
| Shareholder Yield % | 1.36 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 58.28 | |||||
| Operating Margin % | 23.99 | |||||
| Net Margin % | 19.24 | |||||
| FCF Margin % | 10.58 | |||||
| ROE % | 21.44 | |||||
| ROA % | 15.48 | |||||
| ROIC % | 21.95 | |||||
| ROC (Joel Greenblatt) % | 52.29 | |||||
| ROCE % | 28.07 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 19.86 | |||||
| Forward PE Ratio | 20.56 | |||||
| PE Ratio without NRI | 20.83 | |||||
| Shiller PE Ratio | 35.99 | |||||
| Price-to-Owner-Earnings | 17.87 | |||||
| PEG Ratio | 1.1 | |||||
| PS Ratio | 3.87 | |||||
| PB Ratio | 3.93 | |||||
| Price-to-Tangible-Book | 4.65 | |||||
| Price-to-Free-Cash-Flow | 36.71 | |||||
| Price-to-Operating-Cash-Flow | 19.66 | |||||
| EV-to-EBIT | 13.93 | |||||
| EV-to-Forward-EBIT | 14.03 | |||||
| EV-to-EBITDA | 11.58 | |||||
| EV-to-Forward-EBITDA | 11.78 | |||||
| EV-to-Revenue | 3.62 | |||||
| EV-to-Forward-Revenue | 3.33 | |||||
| EV-to-FCF | 34.67 | |||||
| Price-to-Projected-FCF | 2.19 | |||||
| Price-to-Median-PS-Value | 1.13 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.91 | |||||
| Price-to-Graham-Number | 2.09 | |||||
| Price-to-Net-Current-Asset-Value | 7.89 | |||||
| Earnings Yield (Greenblatt) % | 7.18 | |||||
| FCF Yield % | 2.77 | |||||
| Forward Rate of Return (Yacktman) % | 22.33 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:RDY
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Dr Reddy's Laboratories Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 3,279.762 | ||
| EPS (TTM) ($) | 3.787 | ||
| Beta | 0.51 | ||
| Volatility % | 22.7 | ||
| 14-Day RSI | 60.88 | ||
| 14-Day ATR ($) | 1.029735 | ||
| 20-Day SMA ($) | 72.7685 | ||
| 12-1 Month Momentum % | 19.57 | ||
| 52-Week Range ($) | 53.12 - 77.72 | ||
| Shares Outstanding (Mil) | 166.53 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Dr Reddy's Laboratories Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Dr Reddy's Laboratories Ltd Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Dr Reddy's Laboratories Ltd Frequently Asked Questions
What is Dr Reddy's Laboratories Ltd(RDY)'s stock price today?
The current price of RDY is $75.21. The 52 week high of RDY is $77.72 and 52 week low is $53.12.
When is next earnings date of Dr Reddy's Laboratories Ltd(RDY)?
The next earnings date of Dr Reddy's Laboratories Ltd(RDY) is 2024-05-10 Est..
Does Dr Reddy's Laboratories Ltd(RDY) pay dividends? If so, how much?
The Dividend Yield %  of Dr Reddy's Laboratories Ltd(RDY) is 0.65% (As of Today), Highest Dividend Payout Ratio of Dr Reddy's Laboratories Ltd(RDY) was 0.4. The lowest was 0.11. And the median was 0.15. The  Forward Dividend Yield % of Dr Reddy's Laboratories Ltd(RDY) is 0.65%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers